

Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Donald J. Featherstone
Lawrence B. Bugaisky
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Heidi L. Kraus
Edward W. Yee
Albert L. Ferro*
Donald R. Banowitz
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaston
Kimberly N. Reddick
Theodore A. Wood

Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Uhler
Rae Lynn Prengaman
Jane Shershenovich*
George S. Bardmesser
Daniel A. Klein*
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller*
LuAnne M. DeSantis
John J. Figueroa
Ann E. Summerfield
Tiera S. Coston
Aric W. Ledford*
Jessica L. Parezo

Timothy A. Doyle*
Gaby L. Longworth*
Nicole D. Dretar*
Ted J. Ebersole
Jyoti C. Iyer*
Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Helene C. Carlson
Matthew J. Dowd
Aaron L. Schwartz
Katrina Y. Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford

Eric D. Hayes
Michelle K. Holoubek
Robert H. DeSels
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

* Admitted only in Maryland
* Admitted only in Virginia
* Practice limited to
Federal Agencies

March 15, 2004

WRITER'S DIRECT NUMBER:
(202) 772-8762

INTERNET ADDRESS:
NLEITH@SKGF.COM

Art Unit To Be Assigned

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Re: U.S. Utility Patent Application
Application No. 10/734,625; Filed: December 15, 2003
For: **Lipoxygenase Inhibitors as Hypolipidemic and Anti-Hypertensive Agents**
Inventors: ALLAN *et al.*
Our Ref: 1633.0400002/SRL/NJL

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. PTO-1449 citing 67 documents; and
3. Copies of 40 cited documents; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
March 15, 2004
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Nancy J. Leith
Agent for Applicants
Registration No. 45,309

SRL/NJL:cpn
Enclosures



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Allan *et al.*

Appl. No.: 10/734,625

Filed: December 15, 2003

For: **Lipoxygenase Inhibitors as
Hypolipdemic and Anti-
Hypertensive Agents**

Confirmation No.: *To Be Assigned*

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 1633.0400002/SRL/NJL

Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents AR1-AT13 and AL1 are also provided.

Copies of documents AA1 to AD3 are not provided in accordance with the U.S. Patent and Trademark Office pre-OG notice of July 11, 2003, which states "[t]he Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003."

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Nancy J. Leith
Agent for Applicants
Registration No. 45,309

Date: March 15, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



FORM PTO-1449

Page 4 of 13


ATTY. DOCKET NO. 1633.0400002/SRL/NJL	APPLICATION NO. 10/734,625
FIRST NAMED INVENTOR Allan <i>et al.</i>	
FILING DATE December 15, 2003	ART UNIT <i>To Be Assigned</i>

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>4</u>	Gowri, M.S., <i>et al.</i> , "Masoprocol Lowers Blood Pressure in Rats With Fructose-Induced Hypertension," <i>Am. J. Hypertension</i> , 12:744-746, Elsevier Science (1999)
	AS	<u>4</u>	Gowri, M.S., <i>et al.</i> , "Masoprocol decreases rat lipolytic activity by decreasing the phosphorylation of HSL," <i>Am. J. Physiol. Endocrinol. Metab.</i> 279:E593-E600, American Physiological Society (2000)
	AT	<u>4</u>	Guha, M., <i>et al.</i> , "Molecular Mechanisms of Tumor Necrosis Factor α Gene Expression in Monocytic Cells via Hyperglycemia-induced Oxidant Stress-dependent and -independent Pathways," <i>J. Biol. Chem.</i> 275:17728-17739, The American Society for Biochemistry and Molecular Biology, Inc. (2000)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

Page 3 of 13							
 <p>FORM PTO-1449</p> <p>INFORMATION DISCLOSURE STATEMENT</p>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">ATTY. DOCKET NO. 1633.0400002/SRL/NJL</td> <td style="width: 50%;">APPLICATION NO. 10/734,625</td> </tr> <tr> <td colspan="2">FIRST NAMED INVENTOR Allan <i>et al.</i></td> </tr> <tr> <td>FILING DATE December 15, 2003</td> <td>ART UNIT To Be Assigned</td> </tr> </table>	ATTY. DOCKET NO. 1633.0400002/SRL/NJL	APPLICATION NO. 10/734,625	FIRST NAMED INVENTOR Allan <i>et al.</i>		FILING DATE December 15, 2003	ART UNIT To Be Assigned
ATTY. DOCKET NO. 1633.0400002/SRL/NJL	APPLICATION NO. 10/734,625						
FIRST NAMED INVENTOR Allan <i>et al.</i>							
FILING DATE December 15, 2003	ART UNIT To Be Assigned						

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA3	5,342,952	08/30/1994	Butler <i>et al.</i>			10/12/1993
	AB3	5,354,772	10/11/1994	Kathwala			11/24/1993
	AC3	5,356,896	10/18/1994	Kabadi <i>et al.</i>			12/22/1992
	AD3	5,489,691	02/06/1996	Butler <i>et al.</i>			05/15/1995
	AE	6,191,169 B1	02/20/2001	Nadler <i>et al.</i>			11/03/1997
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>3</u>	Das, U.N., "Is Metabolic Syndrome X an Inflammatory Condition," <i>Exp. Biol. Med.</i> 227:989-997, Society for Experimental Biology and Medicine (December 2002)
	AS	<u>3</u>	Feingold, K.R., <i>et al.</i> , "Beneficial effects of cytokine induced hyperlipidemia," <i>Z. Ernährungswiss</i> 37:66-74, Steinkopff Verlag (1998)
	AT	<u>3</u>	Gillard, J., <i>et al.</i> , "L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3- <i>t</i> -butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor," <i>Can. J. Physiol. Pharmacol.</i> 67: 456-464, National Research Council of Canada (1989)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

ATTY. DOCKET NO.
1633.0400002/SRL/NJL

APPLICATION NO.
10/734,625

FIRST NAMED INVENTOR
Allan *et al.*

FILING DATE
December 15, 2003

ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	4,231,938	11/04/1980	Monaghan <i>et al.</i>			06/15/1979
	AB1	4,294,926	10/13/1981	Monaghan <i>et al.</i>			01/23/1980
	AC1	4,319,039	03/09/1982	Albers-Schonberg			08/11/1980
	AD1	4,346,227	08/24/1982	Terahara <i>et al.</i>			06/05/1981
	AE1	4,393,075	07/12/1983	Terao <i>et al.</i>			03/26/1981
	AF1	4,410,629	10/18/1983	Terahara <i>et al.</i>			02/24/1982
	AG1	4,444,784	04/24/1984	Hoffman <i>et al.</i>			12/18/1980
	AH1	4,537,859	08/27/1985	Terahara <i>et al.</i>			11/18/1982
	AI1	4,681,893	07/21/1987	Roth			05/30/1986
	AJ1	4,738,986	04/19/1988	Kneen <i>et al.</i>			03/10/1987
	AK1	4,820,850	04/11/1989	Verhoeven <i>et al.</i>			07/10/1987

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 84/02131					Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	1	Ashida, Y., <i>et al.</i> , "Pharmacological Profile of AA-861, A 5-Lipoxygenase Inhibitor," <i>Prostaglandins</i> 26:955-972, Elsevier Science (1983)
	AS	1	Azhar, S., <i>et al.</i> , "Alteration of the Adrenal Antioxidant Defense System During Aging in Rats," <i>J. Clin. Invest.</i> 96:1414-1424, American Society for Clinical Investigation (1995)
	AT	1	Babu, P.S., and Srinivasan, K., "Hypolipidemic action of curcumin, the active principle of turmeric (<i>Curcuma longa</i>) in streptozotocin induced diabetic rats," <i>Mol. Cell. Biochem.</i> 166:169-175, Kluwer Academic Publishers (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



MAR 15 2004

FORM PTO-1449

PATENT & INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJLAPPLICATION NO.
10/734,625FIRST NAMED INVENTOR
Allan *et al.*FILING DATE
December 15, 2003ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2	4,911,165	03/27/1990	Lennard <i>et al.</i>			12/12/1988
	AB2	4,916,239	04/10/1990	Treiber			07/19/1988
	AC2	4,929,437	05/29/1990	Tobert			02/02/1989
	AD2	5,030,447	07/09/1991	Joshi <i>et al.</i>			03/31/1988
	AE2	5,081,138	01/14/1992	Gillard <i>et al.</i>			12/09/1987
	AF2	5,118,853	06/02/1992	Lee <i>et al.</i>			02/26/1991
	AG2	5,177,080	01/05/1993	Angerbauer <i>et al.</i>			11/26/1991
	AH2	5,180,589	01/19/1993	Joshi <i>et al.</i>			05/20/1991
	AI2	5,189,164	02/23/1993	Kapa <i>et al.</i>			02/20/1990
	AJ2	5,273,995	12/28/1993	Roth			02/26/1991
	AK2	5,290,946	03/01/1994	Lee <i>et al.</i>			11/23/1992

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Bantle, J.P., <i>et al.</i> , "Effects of dietary fructose on plasma lipids in healthy subjects," <i>Am. J. Clin. Nutr.</i> 72:1128-1134, American Society for Clinical Investigation (2000)
	AS	2	Bhattacharjee, P., <i>et al.</i> , "The Effects of a Novel Series of Selective Inhibitors of Arachidonate 5-Lipoxygenase on Anaphylactic and Inflammatory Responses," <i>Ann. New York Acad. Sci.</i> , 307-320, The New York Academy of Sciences (1988)
	AT	2	Brindley, D.N., <i>et al.</i> , "The Involvement of Glucocorticoids in Regulating the Activity of Phosphatidate Phosphohydrolase and the Synthesis of Triacylglycerols in the Liver," <i>Biochem. J.</i> 180: 195-199, The Biochemical Society (1979)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJLAPPLICATION NO.
10/734,625FIRST NAMED INVENTOR
Allan *et al.*FILING DATE
December 15, 2003ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Hallfrisch, J., "Metabolic effects of dietary fructose," <i>FASEB J.</i> 4:2652-2660, Federation of American Societies for Experimental Biology (1990)
	AS	<u>5</u>	Hammes, H.-P., <i>et al.</i> , "Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy," <i>Nat. Med.</i> 9:294-299, Nature Publishing Company (March 2003)
	AT	<u>5</u>	Han, T.S., <i>et al.</i> , "Prospective Study of C-Reactive Protein in Relation to the Development of Diabetes and Metabolic Syndrome in the Mexico City Diabetes Study," <i>Diabetes Care</i> 25:2016-2021, American Diabetes Association (November 2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJL

APPLICATION NO.
10/734,625

FIRST NAMED INVENTOR
Allan *et al.*

FILING DATE
December 15, 2003

ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	6	Hirosumi, J., <i>et al.</i> , "A central role for JNK in obesity and insulin resistance," <i>Nature</i> 420:333-336, Nature Publishing Company (November 2002)
	AS	6	Inoue, I., <i>et al.</i> , "Effect of Troglitazone (CS-045) and Bezafibrate on Glucose Tolerance, Liver Glycogen Synthase Activity, and β -Oxidation in Fructose-Fed Rats," <i>Metabolism</i> 44:1626-1630, W.B. Saunders Company (1995)
	AT	6	Jonkers, I.J., <i>et al.</i> , "Severe Hypertriglyceridemia with Insulin Resistance Is Associated with Systemic Inflammation: Reversal with Bezafibrate Therapy in a Randomized Controlled Trial," <i>Am. J. Med.</i> 112: 275-280, Excerpta Medica, Inc. (March 2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

 FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		Page 7 of 13		
		ATTY. DOCKET NO. 1633.0400002/SRL/NJL		APPLICATION NO. 10/734,625
		FIRST NAMED INVENTOR Allan <i>et al.</i>		
		FILING DATE December 15, 2003	ART UNIT To Be Assigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>7</u>	Knox, A.M., <i>et al.</i> , "Control of Hepatic Triacylglycerol Synthesis. Diurnal Variations in Hepatic Phosphatidate Phosphohydrolase Activity and in the Concentrations of Circulating Insulin and Corticosterone in Rats," <i>Biochem. J.</i> 180: 441-443, The Biochemical Society (1979)
	AS	<u>7</u>	Kraemer, F.B., <i>et al.</i> , "Adrenal Neutral Cholesteryl Ester Hydrolase: Identification, Subcellular Distribution, and Sex Differences," <i>Endocrinol.</i> 143:801-806, The Endocrine Society (March 2002)
	AT	<u>7</u>	Mangaloglu, L., <i>et al.</i> , "Treatment With Atorvastatin Ameliorates Hepatic Very-Low-Density Lipoprotein Overproduction in an Animal Model of Insulin Resistance, the Fructose-Fed Syrian Golden Hamster: Evidence That reduced Hypertriglyceridemia Is Accompanied by Improved Hepatic Insulin Sensitivity," <i>Metabolism</i> 51: 409-418, W.B. Saunders (April 2002)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



MAR 15 2004

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJLAPPLICATION NO.
10/734,625FIRST NAMED INVENTOR
Allan *et al.*FILING DATE
December 15, 2003ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>8</u>	McIntosh, M., <i>et al.</i> , "Opposing Actions of Dehydroepiandrosterone and Corticosterone in Rats," <i>Proc. Soc. Exp. Med.</i> 221:198-206, Society for Experimental Biology and Medicine (1999)
	AS	<u>8</u>	Medicherla, R., <i>et al.</i> , "Impaired activation of AP-1 and altered expression of constituent proteins in rat adrenal during ageing," <i>Mech. Aging Dev.</i> 122:1169-1186, Elsevier Science Ireland Ltd. (June 2001)
	AT	<u>8</u>	Memon, R.A., <i>et al.</i> , "Tumor Necrosis Factor Mediates the Effects of Endotoxin on Cholesterol and Triglyceride Metabolism in Mice," <i>Endocrinol.</i> 132:2246-2253, The Endocrine Society (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

ATTY. DOCKET NO.
1633.0400002/SRL/NJL

APPLICATION NO.
10/734,625

FIRST NAMED INVENTOR
Allan *et al.*

FILING DATE
December 15, 2003

ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	9	Nagai, Y., <i>et al.</i> , "Amelioration of high fructose-induced metabolic derangements by activation of PPAR α ," <i>Am. J. Physiol. Endocrinol. Metab.</i> 282:E1180-E1190, American Physiological Society (January 2002)
AS	9	Okamoto, T., <i>et al.</i> , "Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin," <i>FASEB J.</i> 16:1928-1930, Federation of American Societies for Experimental Biology (December 2002)
AT	9	Park, O.-J., <i>et al.</i> , "Mechanisms of fructose-induced hypertriglyceridaemia in the rat," <i>Biochem. J.</i> 282:753-757, The Biochemical Society (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

Page 10 of 13

ATTY. DOCKET NO.
1633.0400002/SRL/NJL

APPLICATION NO.
10/734,625

FIRST NAMED INVENTOR
Allan *et al.*

FILING DATE
December 15, 2003

ART UNIT
To Be Assigned

INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>10</u>	Radmark, O., <i>et al.</i> , "The Inhibitory Effects of BW 755C on Arachidonic Acid Metabolism in Human Polymorphonuclear Leukocytes," <i>FEBS Lett.</i> 110: 213-215, Elsevier/North Holland (1980)
	AS	<u>10</u>	Rouzer, C.A., <i>et al.</i> , "MK886, a Potent and Specific Leukotriene Biosynthesis Inhibitor Blocks and Reverses the Membrane Association of 5-Lipoxygenase in Ionophore-challenged Leukocytes," <i>J. Biol. Chem.</i> 265:1436-1442, The American Society for Biochemistry and Molecular Biology, Inc. (1990)
	AT	<u>10</u>	Scribner, K.A., <i>et al.</i> , "Masoprocol Decreases Serum Triglyceride Concentrations in Rats With Fructose-Induced Hypertriglyceridemia," <i>Metabolism</i> 49:1106-1110, W.B. Saunders Company (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJLAPPLICATION NO.
10/734,625FIRST NAMED INVENTOR
Allan *et al.*FILING DATE
December 15, 2003ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>11</u>	Tagari, P., <i>et al.</i> , "Assessment of the <i>in vivo</i> biochemical efficacy of orally active leukotriene biosynthesis inhibitors," <i>Agents Action</i> 40:62-71, Birkhäuser Verlag (1993)
	AS	<u>11</u>	Tercyak, A.M., "Determination of cholesterol and cholesterol esters," <i>J. Nutr. Biochem.</i> 2:281-292, Butterworth-Heinemann (1991)
	AT	<u>11</u>	Uchida, K., <i>et al.</i> , "Activation of Stress Signaling Pathways by the End Product of Lipid Peroxidation," <i>J. Biol. Chem.</i> 274: 2234-2242, The American Society for Biochemistry and Molecular Biology, Inc. (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJL

APPLICATION NO.
10/734,625

FIRST NAMED INVENTOR
Allan *et al.*

FILING DATE
December 15, 2003

ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>12</u>	Uysal, K.T., <i>et al.</i> , "Protection from obesity-induced insulin resistance in mice lacking TNF- α function," <i>Nature</i> 389:610-614, Nature Publishing Company (1997)
	AS	<u>12</u>	Ventre, J., <i>et al.</i> , "Targeted Disruption of the Tumor Necrosis Factor- α Gene," <i>Diabetes</i> 46:1526-1531, American Diabetes Association (1997)
	AT	<u>12</u>	Woo, C.-H., <i>et al.</i> , "Tumor Necrosis Factor- α Generates Reactive Oxygen Species via a Cytosolic Phospholipase A ₂ -linked Cascade," <i>J. Biol. Chem.</i> 275: 32357-32362, The American Society for Biochemistry and Molecular Biology, Inc. (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJLAPPLICATION NO.
10/734,625FIRST NAMED INVENTOR
Allan *et al.*FILING DATE
December 15, 2003ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>13</u>	Yoshimoto, T., <i>et al.</i> , "2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA861), a Selective Inhibitor of the 5-Lipoxygenase Reaction and the Biosynthesis of Slow-Reacting Substance of Anaphylaxis," <i>Biochim. Biophys. Acta</i> 713:470-473, Elsevier Biomedical Press (1982)
	AS	<u>13</u>	Yuan, M., <i>et al.</i> , "Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of <i>Ikkβ</i> ," <i>Science</i> 293:1673-1677, American Association for the Advancement of Science (August 2001)
	AT	<u>13</u>	Zavaroni, I., <i>et al.</i> , "Studies of the Mechanism of Fructose-Induced Hypertriglyceridemia in the Rat," <i>Metabolism</i> 31:1077-1083, Grune & Stratton (1982)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.